Supplemental material
Expert Review of Hematology
Volume 14, 2021 - Issue 9
Open access
2,232
Views
5
CrossRef citations to date
0
Altmetric
Original research
Phase II single-arm study of brentuximab vedotin in Chinese patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large cell lymphoma
Yuqin Songa Department of Clinical Oncology, Beijing Cancer Hospital, Beijing, ChinaView further author information
, Ye Guob Department of Oncology, Shanghai East Hospital, Tongji University, Shanghai, ChinaView further author information
, Huiqiang Huangc Department of Medicine, Sun-Yat-sen University Cancer Center, Guangzhou, ChinaView further author information
, Wei Lid Department of Oncology, The First Hospital of Jilin University, Changchun City, ChinaView further author information
, Xiaoyan Kee Department of Hematology, Peking University Third Hospital, Beijing, ChinaView further author information
, Jifeng Fengf Department of Medical Oncology, Jiangsu Cancer Hospital, Nanjing, ChinaView further author information
, Wei Xug Department of Hematology, Jiangsu Province People’s Hospital, Nanjing, ChinaView further author information
, Harry Miaoh Department of Clinical Oncology, Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USAView further author information
, Judith Kinleyh Department of Clinical Oncology, Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USAView further author information
, Gregory Songh Department of Clinical Oncology, Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USAView further author information
, Yi Daih Department of Clinical Oncology, Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USAView further author information
, Hui Wangh Department of Clinical Oncology, Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USAView further author information
& Jun Zhui Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, ChinaCorrespondence[email protected]
View further author information
show allView further author information
Pages 867-875
|
Received 08 Apr 2021, Accepted 10 Jun 2021, Published online: 24 Aug 2021
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.